Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNS561 Food and Formulation Effect in Healthy Volunteers
NCT05353894Phase 1Unknown
- Sponsor
- Genoscience Pharma
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ezurpimtrostat in hepatocellular carcinoma (HCC) and liver cancer (3 arms), sponsored by Genoscience Pharma. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 29 days and Maximum Plasma Concentration at Day 7. Status: unknown.
02
Drugs
ezurpimtrostat
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on NCT05353894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353894.